Zealand Pharma A/S (ZLDPF) Stock Price, News & Analysis

-3.60 (-3.95%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
1,114 shs
Average Volume
895 shs
Market Capitalization
$4.51 billion
P/E Ratio
Dividend Yield
Price Target
ZLDPF stock logo

About Zealand Pharma A/S Stock (OTCMKTS:ZLDPF)

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

ZLDPF Stock Price History

ZLDPF Stock News Headlines

New Zealand Food Price Inflation Weakest Since 2021
Zealand Pharma convenes its Annual General Meeting 2024
See More Headlines
Receive ZLDPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Private households
Current Symbol
Previous Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$49.75 million
Book Value
$2.24 per share


Free Float
Market Cap
$4.51 billion
Not Optionable
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Adam Sinding Steensberg M.D. (Age 50)
    President & CEO
    Comp: $1.73M
  • Ms. Henriette Wennicke (Age 41)
    EVP & CFO
    Comp: $706.47k
  • Mr. Ivan Mourits Moller (Age 52)
    Executive VP & COO
  • Dr. David M. Kendall M.D. (Age 63)
    Chief Medical Officer and Head of R&D
  • Mr. Mads Kronborg
    Head of Investor Relations & Communication
  • Mr. Ravinder Singh Chahil (Age 56)
    EVP & General Counsel
  • Ms. Christina Sonnenborg Bredal (Age 39)
    Executive VP & Chief People Officer
  • Dr. Jens Damsgaard Mikkelsen M.D.
    Head of Molecular Pharmacology
  • Dr. Danilo Verge
    Head of Global Medical Affairs
  • Lykke Romer
    VP & Head of Finance and Accounting

ZLDPF Stock Analysis - Frequently Asked Questions

Should I buy or sell Zealand Pharma A/S stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ZLDPF shares.
View ZLDPF analyst ratings
or view top-rated stocks.

How have ZLDPF shares performed in 2024?

Zealand Pharma A/S's stock was trading at $55.65 at the beginning of the year. Since then, ZLDPF shares have increased by 57.3% and is now trading at $87.55.
View the best growth stocks for 2024 here

Are investors shorting Zealand Pharma A/S?

Zealand Pharma A/S saw a increase in short interest in April. As of April 15th, there was short interest totaling 409,800 shares, an increase of 21.1% from the March 31st total of 338,500 shares. Based on an average daily trading volume, of 4,000 shares, the days-to-cover ratio is presently 102.5 days.
View Zealand Pharma A/S's Short Interest

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (OTCMKTS:ZLDPF) issued its earnings results on Tuesday, February, 27th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by $0.08. The business earned $3.35 million during the quarter, compared to analysts' expectations of $1.97 million. Zealand Pharma A/S had a negative net margin of 213.77% and a negative trailing twelve-month return on equity of 41.49%.

How do I buy shares of Zealand Pharma A/S?

Shares of ZLDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ZLDPF) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners